California abortion providers are preparing backup plans ahead of a major Supreme Court decision that could restrict access to Mifepristone, the most commonly used abortion pill in the United States.
The Supreme Court is currently reviewing Louisiana v. FDA, a case that challenges the federal government’s rules allowing abortion pills to be prescribed through telehealth services and shipped by mail.
A temporary pause issued by Justice Samuel Alito is set to expire on May 11 unless the court intervenes again.
If the lower court ruling takes effect, abortion pills would once again have to be dispensed in person under older Food and Drug Administration rules, ending nationwide mail distribution of the drug.
California providers prepare alternatives
California-based abortion suppliers say they are already preparing to shift quickly to other medications if restrictions on Mifepristone are reinstated.
According to the Los Angeles Times, organizations involved in abortion access have begun planning for the wider use of misoprostol-only regimens. Misoprostol is commonly used alongside mifepristone in medication abortions, but it can also be used on its own.
Dr. Michele Gomez, co-founder of the MYA Network, told the newspaper that supply chains in California are prepared to adapt immediately if the court allows restrictions to move forward.
“We heard about this on Friday and organizations that mail pills were mailing misoprostol on Saturday,” Gomez said. “They already knew what to do.”
Gomez also said abortion access efforts would continue regardless of the court’s decision.
Also Read: Senior Policewoman Dies While Procuring Abortion
“It’s not going away, and it’s not going to slow down,” she said.
The preparations come as abortion rights groups and Republican-led states continue to clash over access to abortion medication following the Supreme Court’s 2022 decision overturning Roe v. Wade.
Court battle centers on FDA authority
The legal dispute began after Louisiana and several other Republican-led states challenged FDA decisions that expanded access to abortion pills over recent years.
On May 1, the Fifth Circuit Court of Appeals ruled that the FDA exceeded its authority by allowing abortion pills to be sent by mail from states where abortion is legal into states with tighter restrictions.
The appeals court decision would restore older requirements that patients obtain mifepristone in person from certified providers.
Justice Alito later issued a temporary administrative stay, blocking the ruling from taking effect while the Supreme Court considers whether to extend the pause or allow the restrictions to proceed.
The court has not announced when it will issue a final decision, but the temporary stay is due to expire on May 11.
The case has become one of the most closely watched abortion battles during President Donald Trump’s current administration, with both anti-abortion groups and abortion rights organizations warning of major national consequences depending on the outcome.
Questions over effectiveness of alternatives
Health experts say replacing Mifepristone with misoprostol alone may create additional medical concerns.
The World Health Organization has stated that the combination of mifepristone and misoprostol is more effective than using misoprostol by itself. The organization also says the two-drug regimen is linked to fewer side effects.
Also Read: New Evidence Exposes How Biden DOJ Weaponized Law to Target Republicans
Despite those concerns, abortion providers say they are ready to continue operating if restrictions are imposed.
Fox News reported that California organizations had already started shipping misoprostol-only options after news of the Fifth Circuit ruling emerged.
The FDA and the MYA Network did not immediately respond to requests for comment from Fox News Digital.
Why this matters
The Supreme Court’s pending decision could reshape abortion access across the United States, especially in states that rely heavily on telehealth prescriptions and mail delivery for abortion medication.
With the May 11 deadline approaching, providers, patients, and state officials are closely watching whether the court will preserve wider access to mifepristone or allow new restrictions to take effect nationwide.
